We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
The call conveyed meaningful early clinical progress — notably a strong MRD clearance signal and ctDNA reduction for cema-cel, favorable outpatient safety signals, encouraging early activity and tolerability for ALLO-329, operational scale-up and a strengthened balance sheet that extends runway into 2029. Major caveats include small interim sample size, the preliminary nature of surrogate biomarker results pending EFS validation, continued dose escalation and limited ALLO-329 maturity, and increased 2026 operating expense guidance. On balance, the call emphasized advancing, differentiated clinical data and execution momentum while acknowledging near-term clinical and financial uncertainties.
Allogene reported a March 31 cash balance of $266.9M and approximately $200.4M of gross proceeds from an April offering, extending its cash runway into Q1 2029; Q1 spend included R&D of $32M (inc. $2.7M non‑cash stock comp), G&A of $14.1M (inc. $5.6M non‑cash), and a net loss of $42.6M or $0.18/share (inc. $8.3M non‑cash). Management modestly raised 2026 operating cash expense guidance from ~ $150M to ~ $165M and GAAP operating expense guidance from ~ $210M to ~ $225M (including an estimated ~$35M of non‑cash stock comp), excluding any M&A impact. Key clinical timing guidance: complete ALPHA3 enrollment by end‑2027 with an interim EFS analysis in mid‑2027 and primary EFS analysis in mid‑2028 (BLA filing to follow as appropriate); ALPHA3 is now enrolling at >60 sites with planned expansion to >80 globally. They also expect an ALLO‑329 update in Q4 2026 after initial dosing (9 patients to date: 3 at 20M cells + cyclophosphamide, 3 at 40M + cyclophosphamide, 3 at 20M without lymphodepletion); management noted the ALPHA3 interim futility (n=24) showed a 58.3% vs 16.7% MRD clearance (41.6‑point absolute difference) and median ctDNA −~98% at day 45 versus +>26% in observation, which they say supports execution within the provided financial runway.
Interim futility analysis (24 patients) showed MRD clearance of 58.3% for cema-cel vs 16.7% for observation — an absolute difference of 41.6 percentage points, supporting biological activity in first-line consolidation for LBCL.
At day 45 median circulating tumor DNA (ctDNA) decreased by ~98% in the cema-cel arm versus an increase of >26% in the observation arm, indicating rapid tumor burden reduction.
No CRS, ICANS or treatment-related hospitalizations reported in the interim ALPHA3 cohort; majority of patients managed entirely in the outpatient setting, supporting potential community administration.
RESOLUTION Phase I basket trial has treated 9 patients across initial cohorts (3 at 20M with LD, 3 at 40M with LD, 3 at 20M without LD). Investigators report early signs of clinical activity and favorable tolerability despite substantially lower cell doses than many competitors.
Dose escalation is ongoing for ALLO-329 with the next cohort at 80 million cells enrolling; company expects to include higher-dose patients in the Q4 2026 update.
ALLO-329 leverages Dagger technology designed to reduce allogeneic rejection; approach has prior clinical validation in ALLO-316 and supportive preclinical data published in Nature Communications.
ALPHA3 is scaling rapidly: enrolling across >60 sites with regulatory approvals and activations begun in Australia and South Korea and plans to expand the Asia-Pacific footprint to over 80 sites; community centers contributed ~1/3 of screening and treatments in the interim cohort.
Cash, cash equivalents and investments of $266.9M as of March 31, 2026, plus ~ $200.4M gross proceeds from April public offering, extending cash runway into Q1 2029.
Company expects ALPHA3 enrollment completion end of 2027, interim EFS analysis mid-2027, primary EFS mid-2028 and plans to pursue a BLA based on those analyses; comprehensive ALLO-329 update planned for Q4 2026.
Hello. Thank you for standing by, and welcome to Allogene Therapeutics First Quarter 2026 Conference Call. [Operator Instructions] Please be aware that today's conference call is being recorded. I would now like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Cassiano, please go ahead.
Thank you, operator, and welcome, everyone, to Allogene's conference call. After the market closed, Allogene issued a press release that provided a business update and financial results for the first quarter of 2026. This press release and today's webcast are available on our website. Following our prepared remarks, we will host a Q&A session and we will aim to keep the call to under an hour. I'm joined today by Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer; and Geoff Parker, Chief Financial Officer. During today's call, we will be making certain forward-looking statements.
These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of our product candidates, commercial market forecast, potential treatment settings and financial guidance, among other things. These forward-looking statements are based on current information, assumptions and expectations that are subject to change. A description of potential risks can be found in our press release and latest ...